Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity

Bristol-Myers Squibb reported balanced segment growth, with the pullback in its stock price presenting an opportunity for investors. The company's earnings and revenue beat expectations, driven by strong performances from its cancer and cardiovascular drugs.

The company also raised its full-year guidance, reflecting its confidence in its product pipeline and growth prospects.